Skin-Contact Wearable and Electrode Biocompatibility Under ISO 10993

Map the complete skin-contact assembly

Identify the backing, pressure-sensitive adhesive, hydrogel or conductive gel, electrode metal, conductive ink, printed circuitry, coating, release liner, edge material and any cleaning or manufacturing residues. Mark what contacts skin directly, what can migrate through another layer and what is isolated in normal use.

Supplier data for one adhesive or film cannot represent the finished assembly automatically. Cure, lamination, printing, sterilization, storage, packaging and interactions between layers can change the patient-contacting state.

Define actual wear, repeated application and cumulative contact

Record maximum wear per application, replacement frequency, total treatment or monitoring period, whether sites overlap, and whether adhesive or gel remains on the skin. A patch worn for hours and repeatedly replaced over weeks creates a different exposure narrative from a single brief measurement.

Use the labelled clinical scenario and foreseeable use. Do not compress repeated exposure into one convenient category without documenting the basis. Consider whether different components contact skin for different periods or whether a conductive medium spreads beyond the device footprint.

Account for sweat, occlusion, motion and the intended population

Real use can include heat, sweat, occlusion, friction, compression, stretching, showering and repeated removal. These conditions may change adhesion, release, skin barrier condition and residue transfer. Assess which conditions are material to the biological question and how the selected evidence represents them.

Population factors can matter: neonatal, elderly, diseased or otherwise vulnerable skin may not be represented by a generic healthy-adult assumption. Damaged skin, wounds, microneedles or transdermal drug delivery fall outside this intact-skin guide and require their own analysis.

Use FDA's intact-skin policy carefully

Attachment G of FDA's ISO 10993-1 guidance describes a policy for certain devices or components that contact intact skin only, are composed of specified materials, and meet all other stated conditions. It is not a blanket exemption. The guidance expressly excludes hydrogels and adhesives used to attach devices directly to skin, including electrode pads and on-body device applications.

A listed backing material does not bring an excluded adhesive, hydrogel, metal, fluid-containing component, novel material or breached-skin use within the policy. Materials that are demonstrably non-contact need not be treated as skin-contact components, but the isolation rationale should be documented. Check every applicable condition and exclusion against FDA's current guidance and recognised-standard record at submission time.

Build a risk-based skin-contact evidence strategy

Use the contact scenario to identify biological effects to address, then connect each question to applicable evidence. Material and process knowledge, chemical characterization, toxicological assessment, prior finished-device data and biological testing can contribute. “Hypoallergenic,” “medical grade,” the same supplier or a trade name is not a safety conclusion.

• Address the complete formulation and finished adhesive or hydrogel state.
• Consider sensitization and irritation in the context of repeated wear and the intended population.
• Investigate leachables, unreacted constituents, degradation and residues when relevant.
• Keep adhesive performance, electrical performance and biological safety as separate conclusions.
• Document evidence limitations and any unrepresented use conditions.

Select representative articles for the finished wearable

The article should preserve the complete skin-contact interface: formulation ranges, coating or adhesive weight, conductive medium, printed layers, lamination, sterilization and relevant aging. A material coupon can answer a narrow question only when the bridge to production processing and the final assembly is justified.

When sizes, wear durations, adhesive formulations or conductive gels differ, use a question-specific family comparison. The largest patch may maximise area while another formulation or longest wear condition drives a different question.

Wearable-electrode biocompatibility review checklist

1. Map every directly contacting and potentially migrating layer or substance.
2. Record single-wear, repeated and cumulative contact duration.
3. Account for sweat, occlusion, motion, removal and realistic skin condition.
4. Identify vulnerable populations and excluded use conditions.
5. Check FDA Attachment G eligibility and exclusions component by component.
6. Bridge supplier and raw-material evidence to the final finished assembly.
7. Justify selected size, formulation, lot, processing and aging state.
8. Keep performance, adhesion and biological-safety conclusions distinct.
9. Obtain qualified biological-safety and jurisdiction-specific regulatory review.

The older FDA ECG-electrode special-controls guidance provides device-specific context; use it alongside current FDA ISO 10993 guidance and the current standards database rather than as a stand-alone universal rule.